J.P. Morgan: Maintains GENSCRIPT BIO (01548) "Overweight" rating, target price HK$41
Eli Lilly (LLY.US) announced a TuneLab collaboration agreement with GenScript Biotech (01548) and others.
J.P. Morgan released a research report stating that Eli Lilly (LLY.US) announced a TuneLab collaboration agreement with GENSCRIPT BIO (01548) and others. The bank maintains its "Overweight" rating on GenScript and a target price of HK$41. Under the agreement, GenScript will provide wet lab services to TuneLab member companies, including gene synthesis, protein expression, purification, and testing under standardized protocols, helping to translate AI-generated drug candidates into experimental results. The bank believes this will help strengthen GenScript's leading position in the AI-driven drug discovery (AIDD) ecosystem.
Related Articles
General Manager Cheng Zhenghui of APT Medical Inc. (688617.SH) plans to reduce his shareholding by no more than 1.5%.
EFORT Intelligent Equipment (688165.SH) shareholder Xinwei Jishi and its concerted parties plan to reduce their shareholding by no more than 3%.
Shanghai Shen Lian Biomedical Corporation (688098.SH): Phase II clinical trial of UB-221 for the treatment of chronic spontaneous urticaria meets primary endpoint
General Manager Cheng Zhenghui of APT Medical Inc. (688617.SH) plans to reduce his shareholding by no more than 1.5%.
EFORT Intelligent Equipment (688165.SH) shareholder Xinwei Jishi and its concerted parties plan to reduce their shareholding by no more than 3%.
Shanghai Shen Lian Biomedical Corporation (688098.SH): Phase II clinical trial of UB-221 for the treatment of chronic spontaneous urticaria meets primary endpoint
RECOMMEND
